Key result
Percutaneous fetal cardiac interventions can interrupt the progression of structural heart diseases such as aortic stenosis, hypoplastic left heart syndrome, and pulmonary atresia.
Percutaneous fetal cardiac interventions offer the potential to interrupt disease progression in specific congenital heart defects, improving perinatal and lifelong outcomes.
Answers are grounded in this paper and cite their sources.
May support fetal intervention in select evolving defects; leaves open need for prospective trials before practice change.
INTRODUCTION: Prenatal diagnosis provides valuable information regarding a variety of congenital heart defects. Some defects occur early in gestation with little change throughout pregnancy, whereas others evolve during mid and late gestation. Fetal cardiac intervention (FCI) affords the opportunity to interrupt progression of disease in this latter category, resulting in improved perinatal and lifelong outcomes. AIM: This chapter addresses three lesions for which percutaneous FCI can be utilized: (1) aortic stenosis with evolving hypoplastic left heart syndrome, for which aortic valvuloplasty may prevent left ventricular hypoplasia and has yielded a biventricular circulation in approximately one third of cases; (2) hypoplastic left heart syndrome with intact atrial septum, for which relief of atrial restriction has potential to improve perinatal survival; and (3) pulmonary atresia with intact ventricular septum and evolving right ventricular hypoplasia, for which pulmonary valvuloplasty has resulted in a biventricular circulation in the majority of patients. The pathophysiology, rationale for intervention, patient selection criteria, procedural technique, and outcomes for each lesion will be reviewed. This chapter will also review complications of FCI and their treatment, and maternal and fetal anesthesia specific to FCI. The importance of a specialized center with experience managing infants delivered after FCI will also be addressed.
No takes yet. Share an insight, caveat, or question.
Tworetzky et al. (2014) conducted a review in Structural Heart Disease. Percutaneous Fetal Cardiac Interventions was evaluated. Percutaneous fetal cardiac interventions can interrupt the progression of structural heart diseases such as aortic stenosis, hypoplastic left heart syndrome, and pulmonary atresia.
Synapse has enriched 10 related papers. Consider them for comparative context: